Equities

Avidity Biosciences Inc

RNA:NMQ

Avidity Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.72
  • Today's Change-0.79 / -1.66%
  • Shares traded1.08m
  • 1 Year change+761.99%
  • Beta0.9210
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Avidity Biosciences Inc have a median target of 64.00, with a high estimate of 96.00 and a low estimate of 51.00. The median estimate represents a 36.99% increase from the last price of 46.72.
High105.5%96.00
Med37.0%64.00
Low9.2%51.00

Earnings history & estimates in USD

On Nov 07, 2024, Avidity Biosciences Inc reported 3rd quarter 2024 losses of -0.65 per share. This result exceeded the -0.71 consensus loss of the 10 analysts covering the company and exceeded last year's 3rd quarter results by 8.45%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+1.61%
Avidity Biosciences Inc reported annual 2023 losses of -2.91 per share on Feb 28, 2024.
Average growth rate-14.45%
More ▼

Revenue history & estimates in USD

Avidity Biosciences, Inc. had 3rd quarter 2024 revenues of 2.34m. This missed the 4.27m consensus estimate of the 8 analysts following the company. This was 4.61% above the prior year's 3rd quarter results.
Average growth rate+2.83%
Avidity Biosciences, Inc. had revenues for the full year 2023 of 9.56m. This was 3.64% above the prior year's results.
Average growth rate+13.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.